Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study

INTRODUCTION: Dupilumab is the first biologic licensed to treat patients with moderate-to-severe atopic dermatitis (AD) who require systemic therapy. PROLEAD was designed to document the real-world effectiveness and safety of dupilumab in patients with moderate-to-severe AD. The present study aims t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thaçi, Diamant, Bauer, Andrea, von Kiedrowski, Ralph, Schenck, Florian, Ertner, Konstantin, Möller, Sophie, Fait, Anja, Bastian, Mike, Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464282/
https://www.ncbi.nlm.nih.gov/pubmed/35984627
http://dx.doi.org/10.1007/s13555-022-00791-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464282/
https://www.ncbi.nlm.nih.gov/pubmed/35984627
http://dx.doi.org/10.1007/s13555-022-00791-1

Ejemplares similares